 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H12N2O2 |
| Molar mass | 216.240 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
Cyclazodone is a centrally actingstimulant drug developed byAmerican Cyanamid Company in the 1960s.[1] The drug is related to other drugs such aspemoline andthozalinone. It displayed a favorable therapeutic index and margin of safety in comparison to pemoline and other N-lower-alkyl-substituted pemoline derivatives.[2] The patents concluded that cyclazodone possessed properties efficacious in reducing fatigue and as a potential anorectic.[3] Structural congeners of pemoline have been described as "excitants with unique properties distinguishing them from the sympathomimetic amines" whilst displaying less stimulatory activity and toxicity compared to amphetamine.[4]
It is included under theWorld Anti-Doping Agency prohibited list.[5]
Cyclazodone has not been evaluated by the United States Food and Drug Administration for use in humans as a nootropic, anorectic, or stimulant and thus safety information is lacking. However, in studies relating to the therapeutic uses of cyclazodone, it was noted that it exhibited less cardiotoxic and hepatotoxic effects than D-amphetamine in studies on mice.[2]
α-Chlorophenylacetyl chloride (1) and 1-cyclopropylurea (2) react to give theamide (3). Theheterocycle cyclazodone is formed on threatment of this withsodium ethoxide.[2][6]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
